Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06911567 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess New Formulations of TEV-56286

A Phase 1 study of Healthy Participants, sponsored by Teva Branded Pharmaceutical Products R&D.

Completed
Registry status
Phase 1
Development phase
47
Enrollment target
1
Study location

NCT06911567 is a Phase 1 study of Healthy Participants that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 47 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06911567, a Phase 1 study of Healthy Participants, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.

COMPLETED
Registry status
Phase 1
Development phase
47 participants
Enrollment target
1
Study location

Study Summary

The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is approximately 70 days which includes a 45 day screening period.

Conditions Studied

Interventions

  • DRUG TEV-56286 Test
  • DRUG TEV-56286 Reference

Study Locations (1)

Florida

  • Teva Investigational Site 12141 - Miramar

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2025-03-10
Est. Completion 2025-06-02
Phase Phase 1

What the Registry Record Tells You About NCT06911567

The ClinicalTrials.gov registry entry for NCT06911567 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (28% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which TEV-56286 Test is the first listed.

NCT06911567 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06911567 about?

NCT06911567 is a clinical study titled "A Study to Assess New Formulations of TEV-56286". The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each particip...

What is the current status of trial NCT06911567?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2025-03-10. Estimated completion is 2025-06-02.

What conditions does trial NCT06911567 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT06911567?

The interventions under investigation include: TEV-56286 Test (DRUG), TEV-56286 Reference (DRUG).

Who is sponsoring clinical trial NCT06911567?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06911567 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.